Kamada Ltd. (KMDA.TA)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Amir London | Chief Executive Officer | 611k | -- | 1969 |
| Mr. Chaime Orlev | Chief Financial Officer | 387k | -- | 1970 |
| Mr. Eran Nir | Chief Operating Officer | 332k | -- | 1973 |
| Mr. Jon R. Knight | Vice President of US Commercial Operations | 307k | -- | 1966 |
| Mr. Boris Gorelik | Vice President of Business Development & Strategic Programs | 410k | -- | 1981 |
| Mr. David Tsur | Co-Founder & Independent Deputy Chairman of the Board | 252k | -- | 1950 |
| Mr. Nir Livneh B.A., L.L.B. | VP, General Counsel & Corporate Secretary | -- | -- | 1980 |
| Ms. Hanni Neheman | Vice President of Marketing & Sales | -- | -- | 1970 |
| Ms. Liron Reshef | Vice President of Human Resources | -- | -- | 1972 |
| Ms. Shavit Beladev | Vice President of Kamada Plasma | -- | -- | -- |
Kamada Ltd.
- Sector:
- Healthcare
- Industry: Drug Manufacturers - Specialty & Generic
- Full Time Employees:
- 378
Description
Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite. The company also distributes imported drug products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX for hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.
Corporate Governance
Recent Events
Recent Events Information Not Available
Upcoming Events
Upcoming Events Information Not Available